Newsroom

Sorted by: Latest

-

Massachusetts Financial Services Company UK Regulatory Announcement: Form 8.3

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION   (a) Full name of discloser: Massachusetts Financial Services Company (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficia...
-

Burjeel Holdings fija el precio de su primer Sukuk de atención médica en la región MENA desde 2018, con una sobredemanda de 3,2 veces

ABU DABI, Emiratos Árabes Unidos--(BUSINESS WIRE)--Burjeel Holdings, grupo líder en atención médica de alta especialización del Consejo de Cooperación del Golfo (CCG) que cotiza en la Bolsa de Valores de Abu Dabi, estableció el precio de su primera emisión de Sukuk senior no garantizada a 5 años bajo la Regulación S, por un valor de $500 millones, con vencimiento en 2031, en el marco de su programa de Sukuk Senior No Garantizado recientemente establecido por valor de $1500 millones. La oferta a...
-

Massachusetts Financial Services Company UK Regulatory Announcement: Form 8.3

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION   (a) Full name of discloser: Massachusetts Financial Services Company (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficia...
-

Samson Rock Capital LLP UK Regulatory Announcement: Form 8.3

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: SAMSON ROCK CAPITAL LLP (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named....
-

Samson Rock Capital LLP UK Regulatory Announcement: Form 8.3

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: SAMSON ROCK CAPITAL LLP (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named....
-

VENU CEO J.W. Roth Featured on The Business Digest Radio Show & Podcast

COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--Venu Holding Corporation ("VENU" or the "Company") (NYSE AMERICAN: VENU), an owner, operator, and developer of premium live entertainment destinations, today announced that Founder, Chairman, and CEO J.W. Roth was featured in an in-depth interview with executive publisher and host Dirk Hobbs, CEO of Colorado Media Group, on The Business Digest Radio Show & Podcast; the radio and podcast outreach of the Southern Colorado Business Digest. In the conve...
-

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy

TOKYO--(BUSINESS WIRE)--Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sanky...
-

Best’s Market Segment Report: U.S. Cyber Market’s Premium Grows Slightly; Surplus Lines Writers Continue to Increase Role

OLDWICK, N.J.--(BUSINESS WIRE)--A pair of distinct sub-markets have evolved within the U.S. cyber insurance space, one dominated by surplus lines carriers writing primary and excess cyber-specific policies and the other focused on endorsements to commercial policies, according to a new AM Best report. The results between the two vary, with third-party claims growing more rapidly within the surplus lines side of the market.The combined overall premiums generated from cyber insurance coverage incr...
-

Ermenegildo Zegna Group Reports Voting Results of the Annual General Meeting Held on June 26, 2026

MILAN--(BUSINESS WIRE)--Ermenegildo Zegna N.V. (NYSE:ZGN) (the “Company” and, together with its consolidated subsidiaries, the “Ermenegildo Zegna Group” or the “Group”) announced that all resolutions submitted to the annual general meeting held on June 26, 2026 were adopted, including, among others: the proposal to approve a dividend distribution of EUR 0.12 per ordinary share, corresponding to a total dividend distribution on the outstanding ordinary shares of approximately EUR 32 million1. th...
-

Burjeel Holdings precifica primeiro Sukuk do setor de saúde na região MENA desde 2018; demanda supera a oferta em 3,2 vezes

ABU DHABI, EAU--(BUSINESS WIRE)--A Burjeel Holdings, grupo líder em saúde de super especialidades no GCC (Conselho de Cooperação do Golfo) com cotação na Bolsa de Valores de Abu Dhabi, precificou sua oferta inaugural de Sukuk sênior sem garantia no valor de US$ 500 milhões nos termos do Regulamento S, com prazo de 5 anos e vencimento em 2031, sob seu recém-criado Programa de Sukuk Sênior Sem Garantia de US$ 1,5 bilhão. A oferta atraiu demanda significativa de investidores internacionais e regio...